Jordan vs Tunisia: Average cost of multi drug-resistant tuberculosis treatment
Jordan
5,124 constant 2022 US$
in 2024
Tunisia
4,560 constant 2022 US$
in 2023
Jordan rank
8th
Tunisia rank
9th
Average cost of multi drug-resistant tuberculosis treatment over time
- Jordan
- Tunisia
How they compare
Jordan currently reports 5,124 constant 2022 US$ against 4,560 constant 2022 US$ in Tunisia, a difference of 564 constant 2022 US$.
That makes Jordan's figure about 1.1 times Tunisia's.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was Tunisia ahead.
Jordan ranks 8th and Tunisia ranks 9th of 92 countries.
Across the 2 decades both report, Jordan averaged higher in 1 and Tunisia in 1.
Head to head by decade
| Decade | Jordan | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5,875 constant 2022 US$ | 4,150 constant 2022 US$ | 1,725 constant 2022 US$ | Jordan |
| 2020s | 3,600 constant 2022 US$ | 3,665 constant 2022 US$ | 65 constant 2022 US$ | Tunisia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Jordan or Tunisia?
- Jordan, at 5,124 constant 2022 US$ against 4,560 constant 2022 US$ in Tunisia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Jordan and Tunisia?
- 564 constant 2022 US$, with Jordan ahead.
- How many years of comparable data are there for Jordan and Tunisia?
- 6 years are reported by both, from 2017 to 2023.
- How do Jordan and Tunisia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Jordan ranks 8th and Tunisia ranks 9th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.